Replies to post #287517 on Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Hydroxychloroquine hype missing key component: Clinical Trials

At a World Health Organization press conference in February, a reporter from the fact-checking group Africa Check asked whether chloroquine was an option. Janet Diaz, head of clinical care for the World Health Organization Emergencies Program, answered that WHO was prioritizing a couple of other drugs in testing along with remdesivir, and acknowledged that Chinese researchers were working on even more. “For chloroquine, there is no proof that that is an effective treatment at this time,” Diaz said. “We recommend that therapeutics be tested under ethically approved clinical trials to show efficacy and safety.”

https://www.wired.com/story/an-old-malaria-drug-may-fight-covid-19-and-silicon-valleys-into-it/?fbclid=IwAR3KWTBuAlWcUbexEc9KWhpaM1_FOp_k8-GDZ3GSG-5ZZAJd3pPuUlPewZ4

The French study (Raoult), that touted a 70% cure rate, has some some pretty significant problems:

While encouraging, it is important to note that this is an unpublished preliminary study, so the results should be viewed with caution. The sample size is small, and the study was non-randomized, meaning people were allocated to different interventions using non-random methods. The study was also "unblinded," meaning that all parties—i.e. the medical staff, patients and researchers—were aware of the treatments the participants received.

https://www.newsweek.com/hydroxychloroquine-malaria-drug-coronavirus-fda-1493293?utm_source=MSN&utm_medium=Feed&utm_campaign=Partnerships

Trump was wrong. Hydroxychloroquine is not FDA approved for COVID-19. However, since it is FDA approved for Malaria, doctors can prescribe it for any malady. Since there is no FDA approved vaccine or therapy for COVID-19, I think the hyping of hydroxychloroquine is, at least in part, an attempt to console the public by giving them hope.

Despite its many problems, I found the French (Raoult) study interesting:

In fact, after six days, 70 percent of the treated patients were considered cured, meaning that the virus was no longer detected in samples taken from them, compared to 12.5 percent of the control group patients. Furthermore, all six patients who were treated with both hydroxychloroquine and the antibiotic azithromycin tested negative for the virus after six days.

https://www.newsweek.com/hydroxychloroquine-malaria-drug-coronavirus-fda-1493293?utm_source=MSN&utm_medium=Feed&utm_campaign=Partnerships

So, it appears this unpublished, non-peer reviewed study suggests that Hydroxychloroquine has some anti-viral properties that are enhanced with the combo-therapy use of an antibiotic (azithromycin). If Brilacidin is determined to have anti-viral properties, the antibiotic is already built-in. IMO, Brilacidin can meet or beat Hydroxychloroquine's safety profile with fewer less severe side effects.

As I look into the hype surrounding Hydroxychloroquine, I am becoming more confident about Brilacidin's ability to become a major player (therapeutic and/or vaccine) in ending the COVID-19 pandemic.

Message in reply to:

Hydrochloriquine is a therapeutic drug aimed at symptoms. Brilicidin is actually being tested for both vaccine capability and therapeutic. I know nothing about the vaccine potential but think the therapeutic angle has a good chance at success.

Go Leo!